Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorHannover Medical School

About this trial

The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.

The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:

Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.

Participants will:

* Receive 10 sessions of iTBS over the course of 2 weeks * Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.

The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of schizophrenia (ICD-10: F20.-)

Age: 18-65 years

Ability to give informed consent

Signed informed consent form

Disqualifiers

Any electronic implants

Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)

Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)

Claustrophobia

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intermittent theta-burst stimulation

    Device

    Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

  • Sham intermittent theta-burst stimulation

    Device

    Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: iTBSExperimental treatment 1 intervention
Group B: Sham iTBSSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in negative symptoms

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

Time frame
From enrollment to the end of iTBS treatment

Secondary outcomes

1

Change in negative symptoms at 4-week follow-up

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

Time frame
From enrollment to follow-up 4 weeks after the end of iTBS treatment
2

Speech-gesture rating task

Accuracy and speed of evaluations in the Speech-Gesture Rating Task.

Time frame
From enrollment to the end of iTBS treatment
3

Speech-gesture rating task at 4-week follow-up

Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up.

Time frame
From enrollment to follow-up 4 weeks after the end of iTBS treatment
4

Eye-Tracking Task

Changes in eye movements in the Eye-Tracking Task.

Time frame
From enrollment to the end of iTBS treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.